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Abstract
Patients with myelofibrosis (MF) experience an array of symptoms that impair health-related quality of life (HRQoL). 
Fedratinib, an oral, selective Janus-kinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, 
phase III JAKARTA study in adult patients with intermediate- or high-risk JAK-inhibitor-naïve MF. The effect of fedratinib 
400 mg/d on patient-reported MF symptoms and HRQoL in JAKARTA was assessed. Participants completed the mod-
ified Myelofibrosis Symptom Assessment Form (MFSAF v2.0), which evaluates 6 key MF symptoms (night sweats, early 
satiety, pruritus, pain under ribs on the left side, abdominal discomfort, bone/muscle pain). The modified MFSAF v2.0 was 
completed during the first 6 treatment cycles and at end of cycle 6 (EOC6). Symptom response was a ≥50% improvement 
from baseline in total symptom score (TSS). Overall HRQoL was assessed by EQ-5D-3L health utility index (HUI) score. 
The MFSAF-evaluable population comprised 91/96 patients randomized to fedratinib 400 mg and 85/96 patients random-
ized to placebo. Mean baseline TSS was 17.6 and 14.7 for fedratinib and placebo, respectively, and mean EQ-5D-3L 
HUI was 0.70 and 0.72. Fedratinib elicited statistically significant and clinically meaningful improvements in TSS from 
baseline versus placebo at all postbaseline visits. Symptom response rates at EOC6 were 40.4% with fedratinib and 8.6% 
with placebo (OR 7.0 [95% CI, 2.9-16.9]; P < 0.001), and a significantly higher proportion of fedratinib-treated patients 
achieved clinically meaningful improvement from baseline on the EQ-5D-3L HUI at EOC6 (23.2% versus 6.5%; P = 0.002). 
Fedratinib provided clinically meaningful improvements in MF symptoms and overall HRQoL versus placebo in patients 
with JAK-inhibitor-naïve MF.
Introduction
Myelofibrosis (MF) is a serious, life-threatening myelopro-
liferative neoplasm (MPN) characterized by stem cell-derived 
clonal myeloproliferation, abnormal cytokine expression, bone 
marrow fibrosis, splenomegaly, extramedullary hematopoie-
sis, constitutional symptoms, cachexia, leukemic progression, 
and shortened survival.1 Patients with MF can experience sub-
stantially compromised health-related quality of life (HRQoL) 
because of disease-related constitutional symptoms (fatigue, 
weight loss, night sweats), symptoms associated with hepa-
tosplenomegaly (early satiety, pain under ribs on the left side, 
abdominal discomfort), and the need for blood transfusions.2,3 
Patients with MF report worse HRQoL compared with con-
trol subjects without MF, and even compared with patients 
with other BCR-ABL-negative MPNs (polycythemia vera [PV], 
essential thrombocythemia [ET]).4
Fedratinib is an oral, selective inhibitor of Janus kinase 2 
(JAK2) approved in the United States for treatment of adult 
patients with intermediate-2 or high-risk MF. The recommended 
starting dose of fedratinib is 400 mg/d, taken in continuous 
28-day treatment cycles.5 The randomized, placebo-controlled, 
phase III JAKARTA study (NCT01437787) assessed fedratinib 
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in adult patients with intermediate-2 or high-risk, JAK-inhibitor-
naïve MF. In JAKARTA, fedratinib was associated with signifi-
cant improvements in spleen volume by the end of 6 treatment 
cycles compared with placebo: the spleen volume response rate 
(≥35% spleen volume reduction [SVR] from baseline) with fed-
ratinib 400 mg/d at the end of cycle 6 (EOC6), with a follow-up 
scan 4 weeks later, was 36%, compared with 1% in the placebo 
arm (P < 0.0001).5,6
Objective measures of MF disease control, such as reduced 
splenomegaly, do not always correlate with improvements in 
patient-reported HRQoL. These analyses were performed to 
thoroughly evaluate patient-reported outcomes with fedratinib 
400 mg/d versus placebo during the first 6 treatment cycles (~24 
wks) in the JAKARTA trial.
Methods
Study design, eligibility criteria, clinical efficacy, and safety 
outcomes have been reported elsewhere.6,7 Briefly, eligible 
patients were aged ≥18 years, with intermediate-2 or high-risk 
primary or secondary (post-PV or post-ET) MF, palpable sple-
nomegaly (≥5 cm below the left costal margin), platelet counts 
≥50 × 109/L, and Eastern Cooperative Oncology Group perfor-
mance status (ECOG PS) scores of ≤2. Prior therapy with JAK 
inhibitors was not allowed. Patients were randomized 1:1:1 to 
fedratinib 400 mg, fedratinib 500 mg, or placebo, self-adminis-
tered orally once-daily for at least 6 continuous 28-day treat-
ment cycles. At EOC6 (or earlier in cases of disease progression), 
patients randomized to placebo could crossover to fedratinib. 
As noted, this report details outcomes among patients random-
ized to fedratinib 400 mg (the approved starting dose) or pla-
cebo; the 500 mg daily fedratinib dose evaluated in JAKARTA 
was not more effective than the 400 mg dose and was associated 
with a less favorable safety profile.6 Due to the prospectively 
planned crossover, comparative endpoints are limited to the ini-
tial 6-cycle double-blind randomized treatment period.
Symptom responses were assessed using the modified 
Myelofibrosis Symptom Assessment Form (MFSAF, version 
2.0),3 which measures patient-reported severity of 6 key MF 
symptoms: night sweats, early satiety, pruritus, pain under the 
ribs on the left side, abdominal discomfort, and bone or mus-
cle pain, each scored from 0 (absent) to 10 (worst imaginable). 
Patients reported modified MFSAF v2.0 scores in an e-diary on 
each of the 7 days before day 1 of each treatment cycle, and 
during the 7 days before EOC6. A daily total symptom score 
(TSS) was calculated by summing the 6 individual symptom 
scores and was considered missing if any individual symptom 
score was missing on that day. The weekly TSS was the average 
of the daily scores for patients with nonmissing daily TSS for ≥5 
days from that week. The weekly TSS score ranged between 0 
and 60, with a higher score indicating a higher level of sympto-
mology. Modified MFSAF compliance rate at each assessment 
was the number of patients with nonmissing scores divided 
by the number of patients eligible for assessment at that visit. 
Completion rates were calculated by dividing the number of 
patients with nonmissing TSS at a given visit by the intent-to-
treat (ITT) population at baseline.
The following modified MFSAF v2.0 endpoints were assessed: 
mean changes from baseline in TSS and individual symptom 
scores, symptom response rate, durability of symptom response, 
time to first symptom response, and time to definitive symp-
tom improvement. The MFSAF-evaluable population included 
all patients with a valid TSS at baseline, defined as available 
daily TSS for ≥5 of the 7 days in the week before cycle 1 day 1 
(C1D1).
Within each treatment arm, changes from baseline TSS and 
individual symptom scores at were assessed at each postbaseline 
visit by paired 1-sample, 2-sided t-test. Differences between fed-
ratinib and placebo in mean score changes from baseline were 
compared using 2-sample t-tests with pooled variances. Effect 
sizes for between-group differences in mean modified MFSAF 
v2.0 score changes from baseline were estimated using Hedges’ 
g.8 An effect size of ≥0.5 is a commonly used threshold to deter-
mine whether between-group differences are clinically mean-
ingful, but others have advocated for a threshold of ≥0.2.9 For 
these analyses, small, medium, and large treatment effects were 
defined as effect sizes of 0.20 to <0.50, 0.50 to <0.80, and ≥0.80, 
respectively.10
Symptom response, defined as a reduction of ≥50% in 
weekly TSS from baseline, was assessed at each postbaseline 
visit among patients with a baseline TSS > 0. A logistic regres-
sion model was used to compare symptom response rates in 
the fedratinib 400 mg and placebo arms at each postbaseline 
visit. Adjusted odds ratios (ORs) and corresponding 95% confi-
dence intervals (CIs) and P values were estimated controlling for 
baseline scores. Durability of symptom response was measured 
by the number of the postbaseline assessment visits in which 
patients achieved a symptom response. Time to response was 
estimated using Kaplan-Meier methods, and compared between 
treatment arms using Cox proportional hazards regression anal-
yses including treatment arm and baseline scores as covariates.
Overall HRQoL during treatment was assessed by 
EQ-5D-3L,11 a nondisease specific, self-administered instru-
ment that includes a descriptive questionnaire and a visual ana-
logue scale (VAS). The descriptive questionnaire measures level 
of impairment in 5 key dimensions—mobility, self-care, usual 
activities, pain, and anxiety/depression—as rated on a 3-level 
severity scale (no problems, some problems, extreme problems). 
Weighted scores from the 5 are used to determine a composite 
“health utility index,” with higher scores representing a better 
health state. For these analyses, health utility index scores were 
derived using published guidance from United Kingdom popula-
tion preferences,12 with a range from –0.594 to 1.0. The EQ-5D 
VAS is a single-item visual scale for patient-rated health on a 
vertical scale ranging from 0 (worst imaginable health state) to 
100 (best imaginable health state).
In JAKARTA, patients completed the EQ-5D-3L at baseline 
(C1D1) and EOC6. Baseline EQ-5D-3L completion rate was cal-
culated as the number of patients with nonmissing health utility 
(ie, all 5 items completed) and VAS assessments, divided by the 
total number of patients in the ITT population. Compliance rate 
was the number of patients with nonmissing scores divided by 
the number of patients eligible for assessment at a given visit.
EQ-5D-3L endpoints included changes in health utility index 
and VAS scores from baseline at EOC6, and proportions of 
patients in each arm who experienced clinically meaningful 
improvement or deterioration from baseline. There is as yet no 
consensus definition of response based on changes in EQ-5D-3L 
health utility scores for patients with MF. Data regarding clini-
cally meaningful change in health utility scores for patients with 
other hematological or oncological illnesses13 were the basis for 
the “minimally important differences” (MIDs) used in this study 
to interpret changes from baseline at the individual and group 
levels. Accordingly, clinically meaningful improvement from 
baseline on the health utility index was defined as a ≥0.08-point 
increase, and clinically meaningful deterioration was defined as 
a ≥0.10-point reduction.13 For the EQ-5D VAS, an MID of ±7 
points was used to determine clinically meaningful improve-
ment (+7) or deterioration (–7 points) from baseline.14 EQ-5D-
3L–evaluable patients had nonmissing health utility and VAS 
scores at baseline (ie, C1D1).
Other assessments included comparisons of within-group 
and between-group least-square (LS) mean score changes from 
baseline at each postbaseline timepoint estimated using anal-
ysis of covariance (ANCOVA) models controlling for baseline 
instrument score. Within- and between-group differences in 
LS mean changes from baseline were also assessed by mixed 
model repeated measures (MMRM) analysis, with changes from 
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baseline scores as the dependent variable. The MMRM model 
had the intercept and time as the random effects and the follow-
ing covariates as fixed effects: baseline domain score, treatment 
group, time, and a treatment-by-time interaction. Responder 
analyses compared the proportion of patients in each arm who 
achieved clinically meaningful improvement (modified MFSAF 
and EQ-5D-3L) or deterioration (EQ-5D-3L only) at each visit, 
defined as a ≥50% reduction from baseline in TSS or individ-
ual symptom scores on the modified MFSAF v2.0 and using the 
MIDs described above on the EQ-5D-3L. Responder analyses 
were performed with logistic regression methods; adjusted ORs, 
95% CIs, and P values were estimated controlling for baseline 
scores. To assess potential heterogeneity in treatment effects, 
modified MFSAF v2.0 symptom response rates at EOC6 were 
assessed among patient subgroups defined by baseline char-
acteristics. Finally, to evaluate potential associations between 
patient-reported outcomes and objective spleen volume changes 
with fedratinib, changes in MFSAF and EQ-5D-3L scores 
among patients randomized to fedratinib 400 mg were strati-
fied by degree of SVR from baseline at EOC6: <10% (including 
spleen volume increases), 10% to <35%, or ≥35%. Analysis of 
variance (ANOVA) methods were used for pairwise compari-
sons of changes from baseline in each fedratinib SVR subgroup 
versus the overall placebo arm for patients with available TSS 
and spleen volume data at both baseline and EOC6.
All analyses were performed using SAS version 9.4 or higher. 




Overall, 96 patients were randomized to fedratinib 400 mg 
and 96 were randomized to placebo. The MFSAF-evaluable 
population comprised 91 patients (95%) in the fedratinib 
400 mg arm and 85 patients (89%) in the placebo arm. The 
EQ-5D-3L health utility and VAS evaluable populations com-
prised 95 (99%) and 91 (95%) fedratinib-randomized patients, 
respectively, and 92 (96%) and 88 (92%) placebo-randomized 
patients. Baseline demographic and disease characteristics in 
the MFSAF-evaluable populations (Supplemental Digital Table 
1; http://links.lww.com/HS/A157) were consistent with the ITT 
population6 and were mostly comparable between treatment 
arms. Compared with the placebo arm, the fedratinib 400 mg 
arm included a lower proportion of patients aged ≥65 years 
(35% in the fedratinib 400 mg arm versus 56% in the placebo 
arm) and fewer patients with high-risk MF (40% versus 56%, 
respectively), and had a longer median time from MF diagnosis 
to study entry (3.6 versus 2.4 yrs). In all, 72 patients (75%) in 
the fedratinib arm and 50 patients (52%)  in the placebo arm 
had nonmissing TSS scores at baseline and EOC6.
Modified MFSAF v2.0
Compliance rates were high (>80% of eligible patients at 
each time-point) in both treatment groups at C2D1 through 
C6D1. At EOC6, compliance rate was significantly greater in 
the fedratinib arm than in the placebo arm (96% versus 79%, 
respectively; P = 0.002) (Supplemental Digital Figure 1; http://
links.lww.com/HS/A157). Completion rate declined over time 
in both treatment groups but was significantly higher in the fed-
ratinib 400 mg arm (78%) than in the placebo arm (58%) at 
EOC6 (P = 0.005).
At baseline, mean weekly TSS and individual symptom scores 
on the modified MFSAF v2.0 were slightly higher in the fedra-
tinib arm than in the placebo arm (Table 1), although overall 
mean symptom scores (which ranged from 2.1 to 3.3) suggested 
that MF symptoms were generally mild in severity at study 
entry. Patients reported early satiety as the most problematic 
symptom at baseline.
During treatment, mean TSS changes from baseline indicated 
significant improvement with fedratinib 400 mg compared with 
placebo at all postbaseline visits through EOC6, with generally 
medium effect sizes (Figure 1). At EOC6, the mean [±SD] change 
from baseline in TSS among evaluable patients was –8.0 [13.0] 
in the fedratinib arm (n = 72) and +0.6 [7.7] in the placebo arm 
(n = 50) (effect size –0.67 [95% CI –0.97 to –0.36], and the major-
ity of evaluable patients in the fedratinib 400 mg arm achieved a 
reduction in TSS from baseline (Figure 2A). These findings were 
confirmed by supporting ANCOVA analyses: fedratinib was asso-
ciated with significant improvements in LS mean changes from 
baseline at all assessment time points through EOC6, and LS 
mean changes at each time point were significantly greater with 
fedratinib 400 mg compared with placebo (Supplemental Digital 
Table 2; http://links.lww.com/HS/A157). Between-group results 
were further confirmed in the MMRM analysis (Supplemental 
Digital Table 3; http://links.lww.com/HS/A157). Statistically sig-
nificant between-group differences in mean changes from base-
line favoring fedratinib were also observed for all 6 modified 
MFSAF v2.0 symptoms across all visits except for pruritus scores 
at 1 assessment (EOC6) (Figure  3). Fedratinib was associated 
with clinically meaningful medium effect sizes relative to placebo 
starting at C3D1 for night sweats, early satiety, and pain under 
ribs on the left side; small, medium, and large effect sizes were 
seen for abdominal discomfort; and differences in pruritus and 
bone or muscle pain scores were associated with small effect sizes 
(0.20 to <0.50) at almost all postbaseline assessments. Symptom 
scores in the placebo arm generally remained at or above base-
line levels across postbaseline visits.
The symptom response rate (ie, ≥50% reduction in TSS from 
baseline) at EOC6 was significantly greater with fedratinib ver-
sus placebo: 40% versus 9%, respectively (Supplemental Digital 
Figure 2; http://links.lww.com/HS/A157), with an OR for 
response with fedratinib of 7.0 (95% CI, 2.9-16.9; P < 0.001). 
Median time to first symptom response was 11.9 weeks in the 
fedratinib arm and was not reached (NR) in the placebo arm 
(hazard ratio [HR] 2.8 [95% CI, 1.7-4.7]; P < 0.0001). The 
difference between fedratinib and placebo in time to definitive 
symptom improvement was also statistically significant: 16.1 
Table 1.
Baseline Scores on the Modified MFSAF and EQ-5D-3L 
Instruments
 
Fedratinib 400 mg Placebo Total
Mean [SD]
MFSAFa N = 91 N = 85 N = 176
 Total symptom score 17.6 [13.5] 14.7 [12.0] 16.2 [12.8]
  Night sweats 3.0 [3.0] 2.4 [2.9] 2.7 [2.9]
  Pruritus 2.3 [2.7] 1.9 [2.3] 2.1 [2.5]
  Abdominal discomfort 3.1 [2.6] 2.6 [2.5] 2.9 [2.5]
  Early satiety 3.5 [2.6] 3.1 [2.6] 3.3 [2.6]
  Pain under ribs on left side 2.6 [2.7] 2.0 [2.5] 2.3 [2.6]
  Bone or muscle pain 3.2 [2.9] 2.6 [2.5] 2.9 [2.7]
EQ-5D-3L    












aTotal symptom scores range from 0 to 60; individual symptom scores range from 0 to 10 (higher 
scores = worse symptomology).
bScores range from –0.594 to 1.0 (higher scores = better health state).
cScores range from 0 to 100 (higher scores = better health state).
MFSAF = Myelofibrosis Symptom Assessment Form; SD = standard deviation.
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weeks versus NR, respectively (HR 4.2 [95% CI, 2.2-8.2]; 
P < 0.0001) (Figure  4). Nearly one-half (49%) of all MFSAF-
evaluable patients in the fedratinib 400 mg arm achieved a 
symptom response for ≥3 of the first 6 treatment cycles, com-
pared with 9% in the placebo arm.
At EOC6, response rate (≥50% reduction from baseline 
score) for each modified MFSAF v2.0 symptom was signifi-
cantly higher with fedratinib versus placebo, with the greatest 
magnitudes of treatment effect observed in night sweats, early 
satiety, and abdominal discomfort (all P ≤ 0.001) (Supplemental 
Digital Figure 2; http://links.lww.com/HS/A157).
EQ-5D-3L
Compliance rates at EOC6 were significantly higher in the 
fedratinib arm on both the descriptive questionnaire (96%, ver-
sus 82% in the placebo arm; P = 0.007) and VAS (95% versus 
77%; P = 0.003). Completion rates for the descriptive question-
naire in the fedratinib and placebo arms at EOC6 were 77% 
versus 60%, respectively (P = 0.019), and for the VAS were 76% 
versus 57% (P = 0.009).
At baseline, patients in the fedratinib 400 mg and placebo 
arms reported similar mean EQ-5D-3L health utility index and 
VAS scores (Table 1). Baseline EQ-5D-3L scores in this study 
were worse than reference values from a general population 
aged 55–64 years in the United Kingdom15: when applying the 
prespecified MIDs for clinically meaningful deterioration (–0.10 
in health utility score and –7 in VAS score13,14), the overall health 
utility index at baseline in this trial was borderline meaning-
fully worse compared with the reference value (mean 0.71 ver-
sus 0.80, respectively), and baseline mean EQ-5D VAS score 
was substantially lower (61.9 versus 81.7), indicating that the 
HRQoL of study patients was considerably impaired at baseline 
relative to that of healthy individuals.
At EOC6, fedratinib was associated with a significantly 
greater improvement in mean health utility score compared 
with placebo (0.045 versus –0.048, respectively; P = 0.01), 
with a clinically meaningful small effect size of 0.37 (95% 
CI, 0.08-0.66). On the VAS, the mean change from baseline 
at EOC6 was +6.2 in the fedratinib 400 mg arm, compared 
with –0.9 in the placebo arm (P = 0.068). These findings were 
supported by ANCOVA analyses: fedratinib was associated 
with significantly better changes from baseline compared with 
placebo in LS mean health utility score (fedratinib +0.039, pla-
cebo –0.040; P = 0.008) and VAS score (+5.94 versus –0.65; 
P = 0.035) at EOC6, after adjusting for baseline score for each 
assessment. Similarly, a significantly higher proportion of indi-
vidual patients in the fedratinib arm reported clinically mean-
ingful improvement in EQ-5D-3L health utility at EOC6 (23%, 
versus 7% in the placebo arm; OR 5.12 [95% CI, 1.81-14.48]; 
Figure 1. Mean change from baseline in MFSAF TSS by visit, and effect sizes for differences between fedratinib 400 mg vs placebo. MFSAF = 
Myelofibrosis Symptom Assessment Form.
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P = 0.002), and 30% and 19% of evaluable patients in the 
fedratinib and placebo arms, respectively, experienced clini-
cally meaning improvement in VAS scores (OR 1.80 [95% CI, 
0.85-3.78]; P = 0.122). Figure 2B and 2C show changes from 
baseline in EQ-5D-3L health utility and VAS scores for indi-
vidual patients at EOC6.
Figure 2. Mean changes from baseline at end of cycle 6 for patients randomized to fedratinib 400 mg and placebo: (A) MFSAF TSS; (B) EQ-5D-3L 
health utility score; and (C) EQ-5D visual analog scale. MFSAF = Myelofibrosis Symptom Assessment Form; TSS = total symptom score.
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Associations With Spleen Volume Reductions
At EOC6, a clear correlation was observed between degree of 
SVR from baseline with fedratinib and improvements in mod-
ified MFSAF v2.0 TSS and EQ-5D-3L health utility and VAS 
(Figure 5). For fedratinib-treated patients who achieved SVRs of 
≥35%, or SVRs between 10% and <35%, mean TSS improve-
ments and MFSAF symptom response rates at EOC6 were signifi-
cantly greater than those for the overall placebo arm. The mean 
TSS reduction from baseline in patients who received fedratinib 
400 mg and attained <10% SVR was –3.2 (95% CI, 11.1-4.7), 
which was not significantly different from the overall TSS change 
in patients receiving placebo (+0.9; P = 0.34). Improvements in 
health utility and VAS scores at EOC6 were both significantly 
greater for fedratinib-treated patients who achieved ≥35% SVR 
from baseline compared with the placebo arm (Figure 5).
Subgroup Analyses
Symptom response rates at EOC6 were nominally greater 
with fedratinib 400 mg versus placebo across patient subgroups 
defined by baseline demographic and disease characteristics 
(Figure 6). Moreover, TSS improvements with fedratinib within 
patient subgroups were relatively consistent. Fedratinib was also 
associated with higher rates of clinically meaningful improve-
ment and lower rates of clinically meaningful deterioration 
compared with placebo in both EQ-5D-3L health utility and 
EQ-5D VAS scores at EOC6 across all subgroups defined by 
baseline characteristics.
Discussion
At entry to the JAKARTA trial, these patients with interme-
diate-2 or high-risk, JAK-inhibitor-naïve MF reported gener-
ally mild MF-related symptoms on the modified MFSAF v2.0 
at baseline in both treatment groups. Despite this, EQ-5D-3L 
health utility and VAS scores indicated patients in this study had 
considerably impaired HRQoL at baseline relative to an age-
matched general population.13–15
By EOC6, patients treated with fedratinib 400 mg/d were 7 
times more likely to achieve a symptom response than those 
who received placebo. Dampening MF-related inflammation 
may contribute to the effect of fedratinib on ameliorating MF 
symptoms. Abnormal cytokine expression is thought to contrib-
ute to the pathogenesis of MF and related constitutional symp-
toms.16 In a phase II dose-finding study in patients with MF, 
fedratinib treatment was shown to regulate cytokine expression, 
including upregulation of anti-inflammatory adiponectin and 
downregulation of proinflammatory TNF-α.17
Rapid improvement of debilitating symptoms that have a 
negative impact on patients’ quality of life is an important goal 
of MF treatment. The JAK1/2 inhibitor, ruxolitinib, which until 
Figure 3. Mean changes in individual MFSAF symptom scores and effect sizes across visits with fedratinib 400 mg versus placebo. MFSAF = 
Myelofibrosis Symptom Assessment Form.
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recently was the only JAK inhibitor approved for MF treatment, 
was shown to induce symptom responses in 46% of patients 
with JAK-inhibitor-naïve intermediate-2 or high-risk MF in 
the phase III, placebo-controlled COMFORT-I study,18 similar 
to the rate of symptom response with fedratinib 400 mg daily 
(40%) in this study. Thus, the choice of front-line JAK inhibitor 
therapy−now that there is a choice−may depend more on clinical 
factors such as pretreatment platelet counts and anemia severity 
than differential effects on HRQoL.5,19 While the efficacy of rux-
olitinib therapy after fedratinib failure is currently unknown, 
fedratinib treatment after ruxolitinib failure has been shown to 
induce spleen responses in 31% of patients who discontinued 
Figure 4. Time to first response and time to definitive improvement in MFSAF TSS with fedratinib 400 mg and placebo. MFSAF = Myelofibrosis 
Symptom Assessment Form; TSS = total symptom score.
8
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ruxolitinib due failure to attain a response, loss of response, or 
intolerance.20
As early as the first postbaseline assessment (ie, C2D1), treat-
ment with fedratinib was associated with clinically meaning-
ful and statistically significant improvements from baseline in 
individual MFSAF symptom scores and TSS compared with pla-
cebo that were sustained through EOC6. Differences between 
fedratinib and placebo were generally of medium effect size 
(≥0.50) except for pruritis and bone/muscle pain, which had 
small but clinically meaningful effect sizes of ≥0.30. Time to 
Figure 5. Relationships between level of spleen volume reduction in the fedratinib 400 mg arm and changes from baseline in (A) MFSAF TSS, (B) 
EQ-5D-3L health utlity index, and (C) EQ-5D visual analog scale. MFSAF = Myelofibrosis Symptom Assessment Form.
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definitive symptom improvement was significantly more rapid 
in the fedratinib arm and symptom responses with fedratinib 
were durable, with approximately one-half of patients in that 
arm achieving ≥50% TSS reductions from baseline at 3 or more 
of the 6 postbaseline visits.
Patients receiving fedratinib 400 mg were also about 5 times 
more likely than patients in the placebo arm to experience clin-
ically meaningful improvement in general HRQoL by EOC6, as 
measured by EQ-5D-3L health utility scores. Although a greater 
proportion of patients in the fedratinib arm showed clinically 
meaningful improvement from baseline at EOC6 in EQ-5D VAS 
scores, the difference between treatment arms was not statisti-
cally significant. Nevertheless, LS mean changes from baseline in 
health utility and VAS at EOC6 were both significantly greater 
with fedratinib versus placebo after adjusting for baseline scores. 
Treatment benefits in favor of fedratinib were observed across 
all patient subgroups defined by baseline demographic and dis-
ease characteristics, and the beneficial effects of fedratinib on 
MF symptoms and HRQoL were similar within these subgroups, 
suggesting minimal heterogeneity of treatment effect. It is worth 
noting that fewer patients in the fedratinib arm were aged >65 
years and a smaller proportion of patients receiving fedratinib 
had high-risk MF at study entry, which may have influenced rel-
ative HRQoL outcomes, although to what extent is unknown.
Overall, there was a clear association at EOC6 between extent 
of SVR and symptom response for patients treated with fedrati-
nib: the greater the SVR, the better the symptom response. Similar 
associations between degree of SVR and symptom improvements 
have been observed with front-line ruxolitinib in a relatively com-
parable patient population in the COMFORT-I study.2 Notably, in 
this study, some patients who had a SVR of ≥35% from baseline 
did not attain a symptom response, and conversely, some patients 
with a ≥50% reduction from baseline TSS from baseline at EOC6 
did not have an accompanying spleen response. When asked, 
MF-related symptoms are reported by a majority of patients with 
the disease, regardless of the presence of palpable splenomegaly.21
In summary, in addition to significantly improving spleen 
volume response compared with placebo, patients treated with 
fedratinib 400 mg/d experienced rapid and sustained clini-
cally meaningful and statistically significant improvements 
in MF-related symptoms and overall HRQoL compared with 
placebo.
Figure 6. Forest plot of MFSAF symptom response with fedratinib 400 mg and placebo at the end of cycle 6 in patient subgroups defined by 
clinically meaningful baseline characteristics. 
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